The 9th Cardiovascular Outcome Trial (CVOT) Summit, held virtually on November 30–December 1, 2023, focused on cardiovascular, kidney, and metabolic outcomes. The summit featured discussions on recent trials, including DAPA-MI, SELECT, STEP-HFpEF, and CLEAR Outcomes, which evaluated the effectiveness of drugs like dapagliflozin, semaglutide, and bempedoic acid in reducing cardiovascular events, improving metabolic outcomes, and treating obesity-related heart failure. The summit also addressed the management of diabetes, heart failure, and chronic kidney disease, emphasizing the importance of diverse patient enrollment and patient-reported outcomes to assess treatment efficacy. Key topics included the role of continuous glucose monitoring (CGM), the impact of diabetes and obesity on non-alcoholic steatohepatitis (NASH) and cancer, and the need for tailored treatments to minimize side effects. The summit highlighted the importance of addressing disparities in treatment effectiveness across different racial and ethnic groups. The 10th CVOT Summit is scheduled for December 5–6, 2024. Key findings from the trials showed significant benefits of these drugs in reducing cardiovascular events, improving metabolic outcomes, and managing heart failure. The summit also emphasized the need for updated guidelines and the inclusion of patient-reported outcomes in clinical decision-making.The 9th Cardiovascular Outcome Trial (CVOT) Summit, held virtually on November 30–December 1, 2023, focused on cardiovascular, kidney, and metabolic outcomes. The summit featured discussions on recent trials, including DAPA-MI, SELECT, STEP-HFpEF, and CLEAR Outcomes, which evaluated the effectiveness of drugs like dapagliflozin, semaglutide, and bempedoic acid in reducing cardiovascular events, improving metabolic outcomes, and treating obesity-related heart failure. The summit also addressed the management of diabetes, heart failure, and chronic kidney disease, emphasizing the importance of diverse patient enrollment and patient-reported outcomes to assess treatment efficacy. Key topics included the role of continuous glucose monitoring (CGM), the impact of diabetes and obesity on non-alcoholic steatohepatitis (NASH) and cancer, and the need for tailored treatments to minimize side effects. The summit highlighted the importance of addressing disparities in treatment effectiveness across different racial and ethnic groups. The 10th CVOT Summit is scheduled for December 5–6, 2024. Key findings from the trials showed significant benefits of these drugs in reducing cardiovascular events, improving metabolic outcomes, and managing heart failure. The summit also emphasized the need for updated guidelines and the inclusion of patient-reported outcomes in clinical decision-making.